Randomized Comparison of Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia: Prolongation of Survival by Hydroxyurea
نویسنده
چکیده
By R. Hehlmann, H. Heimpel, J. Hasford, H.J. Kolb, H. Pralle, D.K. Hossfeld, W. QueiBer, H. Lbffler, B. Heinze, A. Georgii, P.v. Wussow, C. Bartram, M. GrieBhammer, L. Bergmann, U. Essers, C. Falge, A. Hochhaus, U. QueiBer, C. Sick, P. Meyer, N. Schmitz, K. Verpoort, H. Eimermacher, F. Walther, M. Westerhausen, U.R. Kleeberg, A. Heilein, A. Kabisch. C. Barz, R. Zimmermann, G. Meuret, A. Tichelli, W.E. Berdel, L. Kanz, B. Anger, F.J. Tigges, L. Schmid, W. Brockhaus, R. Zankovich, U. Schlafer, 1. WeiBenfels, K. Mainzer, A. Tobler, M. Perker, J. Hohnloser, D. Messener, J. Thiele, T. Buhr, H. Ansari, and the German CML Study Group
منابع مشابه
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
In a randomized multicenter study the influence of hydroxyurea versus busulfan on the duration of the chronic phase and on survival of chronic myelogenous leukemia (CML) was determined. In addition cross resistance and adverse reactions of the drugs were analyzed. From July 1983 to January 1991, 441 CML patients were randomized to receive hydroxyurea or busulfan. Of these, 90.7% were Philadelph...
متن کاملChoice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
We analyzed the outcome of 450 HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in chronic phase performed between 1985 and 1990 and reported to the International Bone Marrow Transplant Registry (IBMTR). All patients received either hydroxyurea (n = 292) or busulfan (n = 158) to treat their CML before transplant. The median interval between diagnosis and tran...
متن کاملRandomized Comparison of Interferon-a, Hydroxyurea, and Busulfan in Chronic Myeloid Leukemia: Response to Kantarjian and Talpaz and to Tura and Baccarani
We appreciate the letters by Kantarjian and Talpaz and by Tura and Baccarani regarding our report.’ Kantarjian and Talpaz compare their retrospective study on 274 interferon-a (R%)-treated chronic myeloid leukemia (CML) patients’ with the IFN arm of our randomized prospective study that compares I F N with hydroxyurea and busulfan. Although the quality of the group’s studies is acknowledged, it...
متن کاملInterferon-a Therapy in Chronic Myelogenous Leukemia: Questions Related to the German Randomized Trial
We read with interest the report of Hehlmann et all in which 133 patients were randomized to interferon-a (IFN-a) therapy (5 X lo6 U/m2/d). The incidence of complete hematologic response. (CHR) was 31% and of complete cytogenetic response was 7%. Their median survival was 5.5 years, which was superior to that of 186 patients treated with busulfan (median survival, 3.8 years; P = .008), but simi...
متن کاملMobilization/transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia.
Chronic myelogenous leukaemia (CML) is a clonal myeloproliferative disease which originates from primitive stem cells and is characterized by a reciprocal translocation between chromosomes 9 and 22. This results in generation of a chimeric gene (BCR/ABL) with increased tyrosine kinase activity. Such modifications cause CML-like myelopoiesis as has been recently demonstrated in mice [1]. Probabl...
متن کامل